Neutropenic events associated with new anticancer treatments, from pathophysiology to practice: a scoping review—NEW Group (Neutropenic Events Working Group)
Neutropenia is a frequent complication of new anti-cancer agents, that requires a dedicated and specific education. The different management procedures differ according to the mechanisms involved, including treatment discontinuation, dose reduction, immunosuppressive drugs use and, G-CSF in specific situations and according to local authorizations and/or recommendations of learned societies.
Authors
- Gabriel Antherieu (ORCID: https://orcid.org/0000-0002-6043-2580)
- William Jacot (ORCID: https://orcid.org/0000-0001-7834-061X)
- Vincent Thibaud (ORCID: https://orcid.org/0000-0003-1648-6167)
- Lodovico Balducci (ORCID: https://orcid.org/0000-0003-3103-2892)
- Pierre Sesques (ORCID: https://orcid.org/0000-0001-8264-822X)
- Claire Falandry (ORCID: https://orcid.org/0000-0001-7267-4723)
- Karima Menia
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Inserm (FR)
- Université Catholique de Lille (FR)
- Moffitt Cancer Center (US)
- Hôpital de la Croix-Rousse (FR)
- Hospices Civils de Lyon (FR)
- Chugai Pharma (United States) (US)
- Hôpital Lyon Sud (FR)
- Laboratoire de recherche en cardiovasculaire, métabolisme, diabétologie et nutrition (FR)
- Institut de Recherche en Cancérologie de Montpellier (FR)
- Hôpital Saint-Vincent-de-Paul (FR)
- Institut National des Sciences Appliquées de Lyon (FR)
Publication Details
- Journal
- Supportive Care in Cancer
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1007/s00520-025-10141-4
- Primary Topic
- Neutropenia and Cancer Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chugai Pharmaceutical